InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,459.10
(
1.11%
)
US TECH 100
18,514.00
(
1.00%
)
Dow Jones
40,589.34
(
1.64%
)
Brent Oil
80.65
(
1.13%
)
Bitcoin
68,002.49
(
0.29%
)
Post# of 4764
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biophud

Send PM Follow Ignore
Followers 0
Posts 394
Boards Moderated 0
Alias Born 08/12/2006

biophud

Re: None

Saturday, 08/12/2006 1:27:45 PM

Saturday, August 12, 2006 1:27:45 PM

Post# of 4764

Here is a patent that I have come across regarding Humanized EGFR antibodies. Wanted to get opinions on its significance (if any). My read of this patent is that it covers CDR-grafted "humanized" derivatives of C225. What product is Imclone trying to protect with this patent? (It is unclear to me). C225 is chimeric and IMC-11F8 is a fully human antibody derived from phage-display. It is my understanding that the eMerck antibody was humanized using this method (if I am wrong please let me know). Would appreciate any insite that you guys have.

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPT...

P.S. I am a long time IMCL long and a long term lurker on the Yahoo Board. I appreciate all the good info on the board.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up